# Should the federal government reschedule cannabis? Implications for marijuana use, research, policy Source: https://www.youtube.com/watch?v=AYGWedecYJg Recap page: https://rapidrecap.app/video/AYGWedecYJg Generated: 2026-02-26T21:43:45.271+00:00 --- ## Quick Overview Federal rescheduling of cannabis from Schedule I to Schedule III is extremely likely to be finalized soon via an administrative rule, which will immediately eliminate the punitive tax Section 280E for state-licensed businesses, although it will not automatically legalize sales or solve major issues like banking access or Food Drug and Cosmetic Act compliance. **Key Points:** - The rescheduling process, initiated under President Biden and resumed under President Trump, is currently held up only by a final procedural step, likely involving a hearing, with odds of completion deemed "extraordinarily high" by legal expert Rob Mikos. - The primary immediate benefit of rescheduling to Schedule III is the automatic elimination of Internal Revenue Code Section 280E, which currently prevents cannabis companies from claiming ordinary tax deductions, a change that could lower consumer prices or increase worker wages. - Dr. Peter Ginspoon, a clinician, notes that rescheduling signals government admission that cannabis is a medicine, contrasting its low documented harms against the high mortality rates of descheduled substances like tobacco and alcohol. - Rescheduling does not automatically legalize cannabis sales, as Schedule III drugs still require DEA licensing, and the sale of marijuana remains in violation of the Food Drug and Cosmetic Act because HHS explicitly stated it is not approving marijuana as a drug. - Ephetaya Harvey argues the move is "a dollar short and a day late," stating that rescheduling fails to address the racialized and class-based harms of the War on Drugs, such as disproportionate targeting of Black communities. - Catalytic, though not immediate, effects of rescheduling include potential long-term improvements in banking access, state-level reform, federal policy shifts, and changes in the international landscape. - Clinically, rescheduling may decrease stigma, potentially lower patient costs (as high costs currently force some off cannabis and back onto opiates), and improve research quality by allowing scientists access to more relevant cannabis products. **Context:** This webinar, hosted by the Petri Flom Center at Harvard Law School and moderated by Dr. Mason Marks, focuses on the implications of the federal government's move to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act, a process expedited by an executive order signed by President Trump in late 2025. The panel includes legal expert Rob Mikos, clinician Dr. Peter Ginspoon, advocate Ephetaya Harvey, and industry advisor Hersh Jane, all discussing the legal, medical, economic, and social consequences of this significant regulatory shift. ## Detailed Analysis The panel overwhelmingly agrees that the finalization of cannabis rescheduling from Schedule I to Schedule III is imminent, pending only a final procedural step, likely a decision by Attorney General Pam Bondi to forgo further hearings. Legal expert Rob Mikos explained that the shift was based on HHS reinterpreting 'currently accepted medical use' to include state medical use authorizations, distinguishing it from the strict FDA approval standard previously required. Clinician Dr. Peter Ginspoon emphasized the symbolic importance of rescheduling as an admission that cannabis is medicine, highlighting that its known harms are far less severe than those of legal substances like alcohol or tobacco, though he stressed the need for better patient education on safe use. Economically, Hersh Jane confirmed the immediate elimination of Section 280E, which currently burdens state-licensed businesses, suggesting savings could flow to consumers or workers, but noted that benefits like banking access are catalytic, not immediate. However, Rob Mikos cautioned that rescheduling does not equate to federal legalization; DEA licensing will still be required for Schedule III substances like ketamine, and the industry will continue violating the Food Drug and Cosmetic Act since HHS is not approving marijuana as a drug. Advocate Ephetaya Harvey criticized the move as insufficient, labeling it "a dollar short and a day late" because it does not address the historical racial and class disparities caused by cannabis prohibition, noting that social equity programs are unlikely to benefit significantly without broader decriminalization efforts. ### Rescheduling Status and Timeline - President Trump accelerated the process, moving from Biden's initial request; finalization requires a final rule from the Attorney General, with odds considered 'extraordinarily high' despite procedural holdups like potential hearings - The historical failure of Congress to pass reform is attributed to current Republican leadership skepticism and the failure to act when Democrats controlled the chambers (2021-2023). ### Legal and Regulatory Hurdles Post-Schedule III - Rescheduling only eliminates 280E; cannabis will remain federally illegal, requiring DEA licensing for handling, similar to Schedule III drugs like ketamine - Companies will still violate the Food Drug and Cosmetic Act because HHS explicitly stated it is not approving marijuana as a drug, which impacts banking and trademarking. ### Economic Impacts of 280E Elimination - Section 280E, referencing only Schedule I and II drugs, will cease to apply, removing a major tax burden for state-licensed businesses - Potential flow of savings includes lower consumer prices or better wages, addressing a retention issue in the industry. ### Medical and Clinical Implications - Rescheduling reduces patient stigma, potentially lowers costs (which currently pushes some patients off cannabis and back to opiates), and improves research access by allowing researchers to study products resembling what patients actually use - Dr. Ginspoon advocates for better education on safer use methods (tinctures over smoking) and notes cannabis's role in harm reduction against opiates and benzodiazepines. ### Social Equity and Decriminalization Gaps - Rescheduling does not remedy harms from prohibition on marginalized communities, and Ephetaya Harvey argues it may cause disharmony with existing state equity programs due to continued economic unsustainability - Full decriminalization or descheduling is advocated for, alongside increased hyper-local organizing and studying international models like Portugal or Canada. ### Federal Agency Roles Post-Rescheduling - The DEA will regulate licensed handling and tracking of cannabis as a Schedule III substance - The FDA's role remains limited to issuing warning letters against unapproved medical claims, as it lacks capacity and has not approved marijuana under the FDCA.